Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,665 Cr revenue.
COGS 29.9%, employees 23.7%.
“Consolidated net revenues of the”
“Consolidated EBITDA to sales for the quarter is 7.”
“Europe expected to grow at 20% plus in revenue over next few years, with margin improvement focus”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | -11.6%▼ | 10.5% |
| ROCE | -2.1%▼ | 13.8% |
| Net Margin | -6.5%▼ | 8.7% |
| EBITDA Margin | 5.1%▼ | 16.0% |
| Debt To Equity | 1.02x▲ | 0.21x |
| Rev Growth 3yr | 2.7%▼ | 5.8% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹1,758 Cr +5.6% | ₹1,665 Cr -8.4% | ₹1,817 Cr +8.9% | ₹1,669 Cr +8.3% | ₹1,541 Cr +24.1% | ₹1,242 Cr +12.2% | ₹1,107 Cr |
| Other Income | ₹5 Cr -1.1% | ₹5 Cr -44.7% | ₹10 Cr +320.9% | ₹2 Cr +0.4% | ₹2 Cr -25.3% | ₹3 Cr +27.9% | ₹2 Cr |
| Total Income | ₹1,764 Cr +5.6% | ₹1,670 Cr -8.6% | ₹1,827 Cr +9.3% | ₹1,671 Cr +8.3% | ₹1,543 Cr +24.0% | ₹1,245 Cr +12.2% | ₹1,109 Cr |
| COGS | ₹507 Cr +1.7% | ₹498 Cr -10.9% | ₹559 Cr +7.3% | ₹521 Cr +14.1% | ₹457 Cr +29.0% | ₹354 Cr +7.2% | ₹330 Cr |
| ₹1,884 Cr +7.9% | ₹1,746 Cr +2.5% | ₹1,703 Cr +15.2% | ₹1,478 Cr +13.1% | ₹1,307 Cr +17.4% | ₹1,113 Cr +3.0% | ₹1,080 Cr | |
| Profit Before Tax | (₹127 Cr) -70.8% | (₹74 Cr) ↓ Decline | ₹136 Cr -29.6% | ₹193 Cr -18.5% | ₹237 Cr +79.2% | ₹132 Cr +361.9% | ₹29 Cr |
| Exceptional Items | (₹7 Cr) ↓ Decline | ₹0.99 Cr -91.4% | ₹12 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| (₹11 Cr) ↓ Decline | ₹4 Cr -90.8% | ₹39 Cr -23.3% | ₹51 Cr -38.2% | ₹82 Cr +109.9% | ₹39 Cr +773.3% | ₹4 Cr | |
| Net Profit | (₹116 Cr) -49.3% | (₹78 Cr) ↓ Decline | ₹97 Cr -31.8% | ₹142 Cr -8.1% | ₹155 Cr +66.4% | ₹93 Cr +285.8% | ₹24 Cr |
| Profit (Owners) | (₹114 Cr) -54.5% | (₹74 Cr) ↓ Decline | ₹98 Cr -30.8% | ₹142 Cr -8.1% | ₹155 Cr +66.4% | ₹93 Cr +285.8% | ₹24 Cr |
| Minority Interest | (₹2 Cr) +41.8% | (₹4 Cr) -188.4% | (₹1 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | (₹2 Cr) +57.1% | (₹4 Cr) ↓ Decline | ₹0.27 Cr -81.3% | ₹1 Cr ↑ Recovery | (₹5 Cr) -519.8% | (₹0.86 Cr) +53.0% | (₹2 Cr) |
| EPS | (₹12.35) | (₹7.99) | ₹10.68 | ₹15.44 | ₹16.80 | ₹10.10 | ₹2.62 |
| Diluted Shares | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Indoco Remedies Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Indoco's formulation plant at Baddi (Plant III) receives EU GMP Certification".
Indoco Remedies Limited has informed the Exchange regarding Demise of Mr Anand Nadkarni , Non- Executive Director of the company on May 15, 2026.
Indoco Remedies Limited has informed the Exchange regarding a press release dated May 14, 2026, titled "Indoco Remedies successfully clears Malta Medicines Authority audit".
Indoco Remedies Limited has informed the Exchange about Transcript
Indoco Remedies Limited has informed the Exchange about Copy of Newspaper Publication
Indoco Remedies Limited has informed the Exchange that Board of Directors at its meeting held on May 07, 2026, recommended Final Dividend of Rs. 0.20 per equity share.
Indoco Remedies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Indoco Remedies Limited has informed the Exchange about ECC on Audited Financial Results for the quarter and year ended 31-03-2026
Indoco Remedies Limited has informed the Exchange about re-appointment of Cost Auditor and Internal Auditor.
Indoco Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Indoco Remedies Limited has informed the Exchange about Schedule of meet
Indoco Remedies Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 ...
Indoco Remedies Limited has informed the Exchange about Transcript
Indoco Remedies Limited has informed the Exchange about Conclusion of Search by GST Authorities
Indoco Remedies Limited has informed the Exchange about Copy of Newspaper Publication